Followers | 128 |
Posts | 2150 |
Boards Moderated | 1 |
Alias Born | 12/27/2007 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, April 09, 2014 8:20:33 AM
Sodium Thiosulfate (STS) Phase 3 Clinical Study Update ..READ
Looks like we hit the Jackpot here ...Maybe this is the reason for the heavy buying by Insiders ! This Low float sleeping giant will explode if final results is also positive .GL
-------
Adherex Announces Sodium Thiosulfate Clinical Study Update
~ Data have been submitted to ASCO 2014~
Adherex’s collaborator the Children’s Oncology Group (COG) posted top-line results from a Phase III trial of Adherex’s lead candidate STS to clinicaltrials.gov last week. The data are incomplete and no statistical analysis was performed. A full analysis of secondary endpoints such as event free survival and overall survival was not posted. Any interpretation should be limited until Adherex reports the full data, which is expected at the American Society of Clinical Oncology (ASCO) meeting in June 2014.
Posted Data, though Incomplete, is Encouraging. According to the posted results, the data regarding the frequency of patients with hearing loss is encouraging, and may support the primary endpoint after a full statistical analysis. The primary endpoint of the trial is hearing protection in pediatric oncology patients undergoing platinum-based chemotherapy.
The posted data show that out of 56 patients in the cisplatin arm of the study, 31 (55%) experienced hearing loss. For the 49 patients treated with STS and cisplatin, 14 (29%) experienced hearing loss. Information posted on the website is incomplete and final results may differ from those presented.
Adherex has announced that COG has already submitted an abstract for presentation at 2014 American Society of Clinical Oncology Meeting. The Company indicated that no other study data is available for public disclosure at this time.
Recent FENC News
- Fennec Pharmaceuticals Announces Management Change • GlobeNewswire Inc. • 07/01/2024 10:00:00 AM
- Fennec Announces Results of Annual Meeting • GlobeNewswire Inc. • 06/25/2024 08:35:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 10:21:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 09:12:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 08:29:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:05:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:05:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:05:13 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 09:24:27 PM
- Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/14/2024 10:03:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/13/2024 08:42:27 PM
- Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024 • GlobeNewswire Inc. • 05/07/2024 10:15:00 PM
- Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/21/2024 10:00:00 AM
- Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024 • GlobeNewswire Inc. • 03/19/2024 10:01:00 AM
- Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand • PR Newswire (US) • 03/18/2024 07:00:00 AM
- Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand • GlobeNewswire Inc. • 03/18/2024 01:00:00 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 03/06/2024 09:07:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:04:59 PM
- Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results • GlobeNewswire Inc. • 02/29/2024 12:04:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 03:47:17 PM
- FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin • GlobeNewswire Inc. • 02/01/2024 10:55:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 10:24:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/05/2024 09:45:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/04/2024 09:42:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 09:30:19 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM